CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando

Cancer Research and Treatment. 2017;49(4):937-946. Published online 2017 January 6 DOI: https://doi.org/10.4143/crt.2016.423

Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando

Cancer Research and Treatment. 2017;49(4):937-946

Link1

Link2 Link3

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

L. Paz-Ares, M.A. Socinski, J. Shahidi, R.R. Hozak, V. Soldatenkova, N. Thatcher, F. Hirsch

Journal of Thoracic Oncology. 2016;11(4):S153

Link1 Link2

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A. Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher

Oncology Research and Treatment. 2016;39(9):539-547

Link1 Link2

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A. Athanasiou, N. Ziras, J. Angel, A. Rapti, S. Lampaki, N. Politis, C. Karanikas, C. Kosmas

Lung Cancer. 2010;68(2):240-247

Link1 Link2

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale

V Gebbia

Lung Cancer. 2003;39(2):179-189

Link1 Link2

P382 A randomized phase II trial of sequential gemcitabine plusvinorelbine followed by gemcitabine plus Ifosfamide versus gemcitabine plus cisplatin in the treatment of chemonaïve patients with stage III and IV non-small cell lung cancer (NSCLC)

G. Teodorescu, T. Ciuleanu, A. Grigorescu, E. Firoiu, D. Ruta Muresan

Lung Cancer. 2005;49:S271

Link1 Link2

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC)

Alexandru Grigorescu, Tudor Ciuleanu, Elena Firoiu, Delia Ruta Muresan, Gabriela Teodorescu, Bruce R. Basson

Lung Cancer. 2007;57(2):168-174

Link1 Link2

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R Hirsch, Alexander V Luft, Aleksandra Szczesna, Tudor E Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat K Galiulin, Beatrix Bálint, György Losonczy, Andrzej Kazarnowicz, Keunchil Park, Christian Schumann, Martin Reck, Henrik Depenbrock, Shivani Nanda, Anamarija Kruljac-Letunic, Raffael Kurek, Luis Paz-Ares, Mark A Socinski

The Lancet Oncology. 2015;16(7):763-774

Link1 Link2

O-220 Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial

Petr Zatloukal, Lubos Petruzelka, Milada Zemanova, Vitezslav Kolek, Jana Skrickova, Milos Pesek, Dimka Sixtova, Jaromir Roubec, Libor Havel, Petr Prusa

Lung Cancer. 2003;41:S65

Link1 Link2

Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer

Pasi A. Jänne, Luis Paz-Ares, Yun Oh, Corinna Eschbach, Vera Hirsh, Nathan Enas, Leslie Brail, Joachim von Pawel

Journal of Thoracic Oncology. 2014;9(1):126-131

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.